Talha Niaz
Mayo Clinic
Internal medicineSurgeryOdds ratioCardiologyRetrospective cohort studyTECPediatricsYoung adultHazard ratioAneurysmWarfarinCoarctation of the aortaFontan procedureCardioversionAortic aneurysmHeart failureAscending aortaAtrial flutterCardiac surgeryVentricleMEDLINETurner syndromeAortaStenosisRegurgitation (circulation)TachycardiaAortic valveBicuspid aortic valveAortic valve stenosisPopulationIntracardiac thrombusCardiopulmonary exercise testGenetic syndromesKommerell diverticulumIn patientExercise capacityPerioperativeAnesthesiaIncidence (epidemiology)Risk factorMedicineEjection fractionComplication
26Publications
8H-index
191Citations
Publications 26
Newest
#1Talha Niaz (Mayo Clinic)H-Index: 8
#2Susan M. Fernandes (Stanford University)H-Index: 33
Last. Donald J. Hagler (Mayo Clinic)H-Index: 88
view all 5 authors...
Abstract Bicuspid aortic valve (BAV) is one of the most common congenital heart defects in children, adolescents and adults. BAV can occur as an isolated lesion or in association with other congenital heart defects, such as coarctation of the aorta or genetic syndromes like Turner syndrome. Although the majority of long term complications associated with BAV manifest later in life, children and adolescents may present with early onset valvular dysfunction or dilation of the aorta. BAV is a heter...
1 CitationsSource
#1Talha Niaz (Mayo Clinic)H-Index: 8
#2Donald J. Hagler (Mayo Clinic)H-Index: 88
Bicuspid aortic valve (BAV) is one of the most common congenital heart defects leading to a significant global financial health burden as a result of its complications (1). BAV can lead to premature aortic valve disease in the form of aortic valve stenosis or regurgitation requiring multitude of interventions on aortic valve, including transcatheter interventions or surgical valve replacement. BAV disease is a continuum of disease process that not only affects the aortic valve but also extends t...
3 CitationsSource
#1Talha Niaz (Mayo Clinic)H-Index: 8
#2Joseph T. Poterucha (Mayo Clinic)H-Index: 18
Last. Donald J. Hagler (Mayo Clinic)H-Index: 88
view all 9 authors...
Background In patients with bicuspid aortic valve (BAV), complications including progressive aortic stenosis and aortic dilatation develop over time. The morphology of cusp fusion is one of the determinants of the type and severity of these complications. We present the association of morphology of cusp fusion in BAV patients with distinctive genetic syndromes. Methods The Mayo Clinic echocardiography database was retrospectively reviewed to identify patients (age ≤ 22 years) diagnosed with BAV ...
11 CitationsSource
#1Talha Niaz (Mayo Clinic)H-Index: 8
#2Joseph T. Poterucha (Mayo Clinic)H-Index: 18
Last. Donald J. Hagler (Mayo Clinic)H-Index: 88
view all 8 authors...
Background Bicuspid aortic valve (BAV) occurs both as an isolated cardiac lesion and in association with congenital heart defects (CHD). Their aim was to identify the incidence and morphology of BAV in patients with coexisting CHD and compare their disease progression to patients with isolated BAV. Methods The Mayo Clinic echocardiography database was retrospectively analyzed to identify pediatric and young adult patients (≤22 years) who were diagnosed with BAV from 1990 to 2015. The morphology ...
16 CitationsSource
#1Alexander C. Egbe (Mayo Clinic)H-Index: 20
#2Heidi M. Connolly (Mayo Clinic)H-Index: 75
Last. Christopher J. McLeod (Mayo Clinic)H-Index: 33
view all 10 authors...
Background The optimal management strategy for atrial tachyarrhythmia in the Fontan population is unknown. Methods Retrospective review of 264 adult Fontan patients with atrial tachyarrhythmia evaluating 3 clinically adopted scenarios: antiarrhythmic drug (AAD) therapy, catheter ablation (CA), and Fontan conversion (FC). These patients were followed up at Mayo Clinic from 1994 to 2014. The study objective was to compare freedom from atrial tachyarrhythmia recurrence (AR) and occurrence of compos...
20 CitationsSource
#1Talha Niaz (Mayo Clinic)H-Index: 8
#2Joseph T. Poterucha (Mayo Clinic)H-Index: 18
Last. Donald J. Hagler (Mayo Clinic)H-Index: 88
view all 5 authors...
Source
#1Alexander C. Egbe (Mayo Clinic)H-Index: 20
#2Heidi M. Connolly (Mayo Clinic)H-Index: 75
Last. David J. Driscoll (Mayo Clinic)H-Index: 71
view all 9 authors...
Background There are limited studies of thrombotic and embolic complications (TEC) in the adult Fontan population. The purpose of the study was to determine the prevalence, risk factors, and outcomes of TECs in this population. Methods Retrospective review of adults with a previous Fontan operation, with follow-up at Mayo Clinic, 1994-2014. Systemic TEC was defined as intracardiac thrombus, ischemic stroke, or systemic arterial embolus. Nonsystemic TEC was defined as Fontan conduit/right atrial ...
29 CitationsSource
#1Alexander C. Egbe (Mayo Clinic)H-Index: 20
#2Heidi M. Connolly (Mayo Clinic)H-Index: 75
Last. Naser M. Ammash (Mayo Clinic)H-Index: 35
view all 10 authors...
Abstract Background To determine if Fontan conversion (FC) resulted in improvement in exercise capacity (EC), and to determine the role of cardiopulmonary exercise test (CPET) in risk stratification of patients undergoing FC. Methods A retrospective review of patients who underwent CPET prior to FC at Mayo Clinic from 1994 to 2014. The patients who also underwent post-operative CPET were selected for the analysis of improvement in EC defined as 10% increase in baseline peak oxygen consumption (V...
15 CitationsSource
#1Alexander C. Egbe (Mayo Clinic)H-Index: 20
#2Heidi M. Connolly (Mayo Clinic)H-Index: 75
Last. David J. Driscoll (Mayo Clinic)H-Index: 71
view all 9 authors...
Abstract Background There are limited data about the risk of thrombotic and embolic complication (TEC) in adults with atrial arrhythmia after Fontan operation. Objectives This study sought to determine the risk of TEC in this population and the role of anticoagulation therapy in TEC prevention. Methods This was a retrospective review of adults with atrial arrhythmia after Fontan operation who were evaluated at the Mayo Clinic between 1994 to 2014. TEC was classified into 2 groups: systemic TEC, ...
44 CitationsSource
#1Talha Niaz (Mayo Clinic)H-Index: 8
#2Joseph T. Poterucha (Mayo Clinic)H-Index: 18
Last. Donald J. Hagler (Mayo Clinic)H-Index: 88
view all 6 authors...
Source